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Prevalence, Molecular Characterization, and Phenotypic
Confirmation of Extended-Spectrum Beta-Lactamases
in Escherichia coli, Klebsiella pneumoniae,
and Klebsiella oxytoca at the Radboud University
Nijmegen Medical Centre in The Netherlands
Patrick D.J. Sturm, Els T.M. Bochum, Sacha V.M. van Mook-Vermulst, Cindy Handgraaf,
Twan Klaassen, and Willem J.G. Melchers
The prevalence and molecular types of extended-spectrum beta-lactamases (ESBLs) were determined during
a 1-year period in unselected clinical nonduplicate isolates of Escherichia coli (n¼ 1,738), Klebsiella pneumoniae
(n¼ 436), and Klebsiella oxytoca (n¼ 208), cultured at the University Medical Centre Nijmegen, The Netherlands.
Isolates identified as ESBL producer by the Phoenix automated system were collected prospectively and sub-
jected to molecular analysis for the most common ESBLs TEM, SHV, and CTX-M, as well as OXA and GES. Both
the Etest ESBL and double-disk synergy test were performed as confirmatory tests. The estimated prevalence of
ESBLs was 2.1% in E. coli, 5.2% in K. pneumoniae, and 2.4% in K. oxytoca. TEM-12 and -26, SHV-5 and -12, and
CTX-M groups 1 and 9 were the most frequent ESBLs found. Isolates identified as ESBLs by the Phoenix were
confirmed by polymerase chain reaction (PCR) in only 42%. In ESBL PCR-positive E. coli and K. pneumoniae, both
confirmatory tests were positive in 95% of the isolates. In 28% of the Etest and 13% of the double-disk synergy
test-positive isolates, PCR could not detect any ESBL gene. In these cases, other resistance mechanisms may play
a role. Confirmatory tests were unreliable for K. oxytoca. A previously described mutation in the K1 enzyme was
detected in one ceftazidime-resistant K. oxytoca. The prevalence of ESBLs in The Netherlands is increasing. The
predominant molecular types of ESBLs detected were comparable to other studies. Phoenix ESBL results need to
be confirmed as advocated by ESBL detection guidelines.
Introduction
W orldwide beta-lactam resistance among Entero-bacteriaceae, mediated by extended-spectrum beta-
lactamases (ESBLs), is increasing. Data on ESBLs from The
Netherlands are, however, limited to only two older studies,
and it is expected that the prevalence of ESBLs is increasing
in The Netherlands, despite restrictive antimicrobial poli-
cies.1,23 Moreover, surveillance programs also report trends
of rising third-generation cephalosporin resistance in Es-
cherichia coli and Klebsiella pneumoniae.8,24 The aim of this
study was to determine the prevalence of ESBLs and to char-
acterize the ESBL genes in consecutive unselected clinical
isolates of E. coli, K. pneumoniae, and Klebsiella oxytoca col-
lected at the University Medical Centre Nijmegen, The
Netherlands. In addition, the detection of ESBLs using the
Phoenix automated microbiology system (Becton Dickinson,
Sparks, MD) as a first screen with confirmation by pheno-
typic tests was evaluated.
Materials and Methods
Bacterial isolates
All E. coli, K. pneumoniae, and K. oxytoca isolated from
clinical specimens in the routine microbiology laboratory
during a 1-year period were identified using the digital
laboratory system. From each patient only the first isolate
indicated by the Phoenix as ESBL and the first isolate not
indicated by the Phoenix as ESBL were selected. A total of
1,738 E. coli, 436 K. pneumoniae, and 208 K. oxytoca were
identified, of which 128 isolates were indicated as ESBLs by
the BD Phoenix, including 65 E. coli, 37 K. pneumoniae, and 26
K. oxytoca. Although it was instructed to the routine clinical
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laboratory to collect and store all isolates that were ESBL
positive by the Phoenix, 26 isolates were not stored. There-
fore, 102 isolates, 50 E. coli, 29 K. pneumoniae, and 23 K. oxy-
toca, were collected prospectively and stored at 208C for
further analysis. Polymerase chain reaction (PCR) and phe-
notypic confirmation tests were performed after two over-
night subcultures.
Molecular characterization of beta-lactamases
The isolates were analyzed for the presence of TEM, SHV,
CTX-M, GES, and OXA by PCR. Total DNA was extracted
using the MagNa Pure Total NA isolation kit (Roche, Almere,
TheNetherlands). PCRswere set up to analyze for the presence
of the ESBL genes in a final volume of 50ml with the PCR
Master mix (Roche) and primers as described previous-
ly.2,3,16,22 After one step at 958C for 5min, the samples were
cycled 40 times (denaturation at 948C for 1min, annealing at
508C for 1min, and extension at 728C for 2min). The presence
of blaCTX-M, blaGES, and blaOXA were analyzed by gel electro-
phoresis. blaTEM, blaSHV, and blaCTX-M genes were further ana-
lyzed by sequence analysis. After purification, the PCRproduct
was sequenced with the BigDye Terminator v3 kit (Applied
Biosystems, Nieuwerkerk a=d IJssel, The Netherlands).
Phenotypic confirmation tests
ESBL confirmatory tests were performed by the Etest ESBL
(AB BIODISK, Solna, Sweden) as well as the cephalosporin–
clavulanate double-disk synergy (DDS) test using both ce-
fotaxime and ceftazidime (Becton Dickinson) as described by
the Clinical and Laboratory Standards Institute [CLSI]
guidelines.6 In brief, Etest strips and antimicrobial disks were
applied to Mueller–Hinton agar (Becton Dickinson) inocu-
lated with a 0.5 McFarland bacterial suspension and incu-
bated at 378C in ambient air overnight for 16–18 hr. Etest
ESBL was positive if the minimum inhibitory concentration
(MIC) for cefotaxime was >0.5 mg=ml and the MIC ratio ce-
fotaxime=cefotaxime þ clavulanic acid was >8, if the MIC for
ceftazidime was >1mg=ml and the MIC ratio ceftazidime=
ceftazidime þ clavulanic acid was >8, if there was a defor-
mation of the growth inhibition zone around cefotaxime or
ceftazidime, or if a phantom zone was present. The DDS test
was positive if the growth inhibition zone around the anti-
microbial disk containing only the cephalosporin increased
to >5mm in the presence of clavulanic acid.
AmpC detection
The presence of AmpC enzymes was investigated by
determining susceptibility to cefoxitin using disk diffusion
according to CLSI criteria.6 A growth inhibition zone of
<18mm was considered suspect for AmpC production.10
Results
Molecular characterization
ESBL was confirmed by PCR and sequence analysis in
43 of the 102 isolates (42%) that were identified as ESBLs
by the Phoenix (Table 1). ESBL genes were detected in 23
E. coli (46%), 14 K. pneumoniae (48%), and 4 K. oxytoca (19%).
Two K. oxytoca were later identified by sequence analysis
as Klebsiella ornithinolytica and both contained SHV-5 (see
below). TEM-derived ESBLs were present in 20 isolates,
SHV-derived ESBLs in 14, and CTX-M enzymes in 11. GES,
OXA, and AmpC enzymes were not detected.
CTX-M and TEM enzymes were the predominant ESBLs
in E. coli. In K. pneumoniae, TEM- and SHV-derived ESBLs
were detected at a similar rate, and in K. oxytoca all four
ESBLs were TEM derived (Table 1).
CTX-M enzymes were only detected in E. coli and be-
longed to the CTX-M-1 and CTX-M-9 groups. TEM-12 and
TEM-26, and SHV-12 and SHV-5 were the predominant TEM
and SHV ESBLs (Table 1).
Of the 59 isolates with no ESBL gene detected, 48 harbored
wild-type beta-lactamase genes or genes with mutations
not previously described as ESBL. CTX-MPCRwas positive in
allK. oxytoca isolates, but in all cases it was due to the presence
of the chromosome-encoded K1 enzyme as was confirmed by
sequence analysis. This has been described previously using
these primers with K. oxytoca.15 Two indole-positive isolates
that were identified as K. oxytoca by the Phoenix did not har-
bor K1, but both isolates were confirmed to be K. ornithinoly-
tica by sequence analysis of the 16S RNA DNA.
Phenotypic confirmation
In E. coli and K. pneumoniae, 95% of the 37 isolates with
positive PCR results for ESBLs were positive with both con-
firmatory tests. Both confirmatory tests were negative in 71%
of 42 E. coli and K. pneumoniae with negative ESBL PCR
results, thereby confirming the occurrence of false-positive
results using the Phoenix. However, 29% (12 of 42) of ESBL
PCR-negative E.coli and K. pneumoniae were positive by con-
firmatory tests. Eleven were positive with the Etest. Five of
these isolates were E. coli with a TEM-1 enzyme (n¼ 2) or no
beta-lactamase (n¼ 3), and six isolates were K. pneumoniae
harboring non-ESBL SHV (n¼ 4), LEN-3 (n¼ 1), and no beta-
lactamase (n¼ 1). Using DDS test, five isolates of ESBL PCR-
negative E.coli and K. pneumoniae were positive. Two of these
isolates were E. coli, both with positive Etest results as
well, one harboring a TEM-1 enzyme and one with no beta-
lactamase detected. Two isolates were K. pneumoniae that also
tested positive with the Etest, one with SHV-11 and one with
no beta-lactamase detected. One was a K. pneumoniae with
combined SHV-11 and TEM-1 and was negative with Etest.
In K. oxytoca, all four isolates that were ESBL PCR positive
were also positive by Etest but negative with DDS test.
However, with the Etest, 88% of the 17 PCR-negative isolates
were positive as well. In contrast, only three (18%) of these
isolates were positive by the DDS test. Of note, these three
isolates were all resistant to ceftazidime (MIC> 32mg=L),
not in keeping with hyperproduction of chromosomal K1
enzyme, whereas all other isolates, including the four isolates
with positive ESBL PCR, were susceptible to ceftazidime
(MIC< 0.5mg=L). In one of the ceftazidime-resistant isolates,
the sequence analysis of the K1 enzyme showed a mutation
resulting in a proline-to-serine substitution at position 167
which was previously shown to be responsible for hydrolysis
of ceftazidime by the K1 enzyme.13,18 In the other cases, no
correlation with K1 mutations was found.
ESBL prevalence
Extrapolating the PCR results obtained with the isolates
that were available for molecular analysis to the total num-
ber of isolates identified by the Phoenix as ESBL, the prev-
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alence of ESBLs in the total population was estimated to be
2.1% in E. coli, 5.2% in K. pneumoniae, and 2.4% in K. oxytoca.
Discussion
Despite the strict antimicrobial policy in The Netherlands,
resistance mediated by ESBLs is increasing as in other parts
of the world. The increasing prevalence of ESBLs threatens
the use of the majority of beta-lactam antibiotics in future
treatment of infections. The prevalence of ESBL-mediated
resistance in The Netherlands in E. coli and K. pneumoniae
was less than 1% in a study in 1995.23 In a study in 2004,
however, the prevalence of ESBLs was estimated to be as
high as 5.6% in E. coli, 2.1% in K. pneumoniae, but none in
K. oxytoca.1 In our study the estimated prevalence in E. coli,
K. pneumoniae, and K. oxytoca was 2.1%, 5.2%, and 2.4%, re-
spectively, based on the PCR results. The long prospective
study period and the large number of isolates investigated in
our study as well as local epidemiology may account for the
small differences found when compared with the contem-
Table 1. Beta-Lactamase Genes and Results of Two Phenotypic Confirmatory Tests
(Etest and Double Disk Synergy Test) in 102 Isolates Identified as Extended-Spectrum
Beta-Lactamases by the Phoenix Automated Microbiology System
Etest DDS test
bla gene Positive Negative Positive Negative
Escherichia coli 50
ESBL 23
TEM 9 TEM-6 1 1
TEM-12 3 1 3 1
TEM-26 3 1 3 1
SHV 4 SHV-5 1 1
SHV-5, TEM-1 2 2
SHV-2, TEM-52 1 1
CTX-M 10 CTX-M-1 2 2
CTX-M-9 2 2
CTX-M-1, TEM-1 3 3
CTX-M-9, TEM-1 3 3
Non-ESBL 27
TEM-1 2 15 1 16
None 3 7 1 9
Klebsiella pneumoniae 29
ESBL 14
TEM 7 TEM-12, LEN2 1 1
TEM-12, LEN3 2 2
TEM-26, SHV-26 3 3
TEM-26, SHV-11 1 1
SHV 7 SHV-5 1 1
SHV-12 3 3
SHV-12, TEM-1 3 3
Non-ESBL 15
SHV-1 2 2
SHV-11 2 3 1 4
SHV-11, TEM-1 1 1
SHV-26 4 4
SHV-36 1 1
LEN-3 1 1
None 1 1
Klebsiella oxytoca 21
ESBL 4
TEM 4 TEM-7 1 1
TEM-12 1 1
TEM-26 1 1
TEM-116 1 1
non-ESBL 17
K1 12 1 2 11
K1, TEM-1 3 1 1 3
Klebsiella ornithinolytica 2
ESBL 2
SHV 2 SHV-5 2 2
ESBL genes are shown in bold.
DDS, double-disk synergy; ESBL, extended-spectrum beta-lactamase.
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porary study in 2004.1 The increasing prevalence of ESBLs
is reflected in the reports by the national surveillance pro-
gram coordinated by the Dutch Foundation of the Working
Party on Antibiotic Policy (Stichting Werkgroep Anti-
bioticaBeleid, or SWAB) which shows that third-generation
cephalosporin resistance was between 2% and 3% in E. coli
and K. pneumoniae collected from unselected hospital wards
in 2007.24 The European Antimicrobial Resistance Surveil-
lance System that collects resistance data from invasive iso-
lates throughout Europe shows that third-generation
cephalosporin resistance in The Netherlands has increased
from <1% in 2001 to 4% in 2007 in E. coli, and from 4% in
2004 to 7% in 2007 in K. pneumoniae.8 Compared with other
parts of the world, ESBL prevalence in The Netherlands re-
mains low. The European Antimicrobial Resistance Surveil-
lance System data show marked differences between
countries, but in 2007 the majority of the European countries,
including The Netherlands, have increasing ESBL preva-
lence compared with previous years, but most countries al-
ready have ESBL prevalence rates of >5%, and some eastern
countries have extremely high rates (>40%). A recent global
study that evaluated tigecycline susceptibility in isolates
from hospital-associated infections showed that the preva-
lence of ESBLs in E. coli and K. pneumoniae was higher in
Europe (7.6% and 13.3%) than in North America (2.2% and
7.5%) but lower compared with the Asia=Pacific Rim (12%
and 22.4%) and Latin America (13.5% and 44%).17
The large genetic diversity in this study among the ESBLs
(11 different types) from a single hospital illustrates the ex-
tent of the ESBL problem. Taking into account the species in
which ESBLs were detected and the concurrent enzymes
present, 22 unique profiles were present among the 43 ESBL
isolates. Still, transmission between patients and plasmid
transfer may contribute to high frequencies of certain types
of ESBLs.
The ESBL genes detected were similar to those detected in
other studies from Europe and the United States. TEM- and
SHV-derived ESBLs, the first ESBLs recognized in the early
80s, were most frequently detected. In this study, most TEM-
derived ESBLs were TEM-12 and TEM-26. These were the
most frequent TEM ESBLs encountered in the United States
as well and have been reported regularly in European stud-
ies.4,19,21 The high frequency of SHV-5 and SHV-12 among
SHV-derived ESBLs is also in line with other studies from
Europe and the United States.4,7 In E. coli, 43% of the ESBLs
were CTX-M enzymes. The CTX-M enzymes are emerging
throughout the world, especially in community-acquired
E. coli with a predominance of group 1 and 9 enzymes as
observed in this study.7 The previously mentioned study
from Amsterdam, The Netherlands, showed that CTX-M
enzymes overall were the predominant ESBL type in that
region, with a marked absence of TEM-derived ESBLs. In
that study the ESBL screen was performed with cefpodoxime
only and included all species of Enterobacteriaceae as well
as nonfermenters with only a limited number of E. coli and
Klebsiellae spp. isolates which may account for these different
findings.1
In 58% of the isolates identified as ESBLs by the Phoenix,
the presence of ESBL genes was not confirmed by PCR. In-
itially, the detection of ESBLs by the Phoenix was reported
to be highly sensitive and specific using preselected well-
defined isolates.20 However, recent large studies evaluat-
ing the Phoenix ESBL detection in the routine laboratory
reported a sensitivity of 93–100% in E. coli and K. pneumoniae
but specificities of only between 67% and 72%, respective-
ly.9,25 Although the more common ESBL genes were inves-
tigated in this study, the presence of ESBL genes not detected
by the primers used, including unknown or rare ESBL genes,
in a number of the Phoenix-positive but PCR-negative iso-
lates can obviously not be excluded.
Similar to other studies that evaluated ESBL detection by
the Phoenix and that showed positive confirmatory tests in
ESBL PCR-negative isolates in 14% and 20%, in our study the
apparent phenotype for ESBL using Etest (n¼ 7), DDS test
(n¼ 1), or both (n¼ 4) was present in 12 of 42 isolates (29%)
of E. coli and K. pneumoniae that were negative for the ESBL
genes investigated.9,25 In four of these isolates, no beta-
lactamase gene was detected at all with the methods used,
thus suggesting the presence of an undetected beta-lactamase
gene. Besides undetected ESBL genes, the ESBL phenotype in
the remaining eight isolates with non-ESBL enzymes detected
may also be explained by hyperproduction of their beta-
lactamases or coexisting changes in the outer membrane.14,26
In contrast to the Phoenix ESBL detection, PCR and con-
firmatory tests were performed after storage of the isolates at
208C. It is unlikely that the positive Phoenix results with
negative PCR and=or confirmatory test results were caused
by the storage conditions. Although plasmids may be lost as
a result of stress, loss of plasmids from Enterobacteriaceae
containing resistance genes as a result of freeze–thawing was
not detected in two studies that specifically addressed this
issue.11,12 In addition, Wiegand et al. did perform Phoenix
ESBL detection simultaneously with PCR and confirmatory
testing and also found a low specificity for the Phoenix.25
Thus, considering the low specificity of the Phoenix re-
ported in other studies and the finding that in the majority
(71%) of the ESBL PCR-negative isolates both confirmatory
tests were negative, most of these ESBL PCR-negative iso-
lates very likely represent false-positive results obtained
with the Phoenix.9,25 Hence, there is a need for confirmatory
testing after screening using the Phoenix or other methods
as advocated in the CLSI guidelines for ESBL detection to
prevent inappropriate reporting of resistance for valuable
therapeutic antimicrobials.6 Indeed, confirmatory testing
using either Etest or DDS test detected 95% of the ESBL PCR-
positive isolates.
ESBL genes were detected in only 4 of the 21 K. oxytoca
isolates and were all TEM derived. In addition, three ESBL
PCR-negative isolates showed high MICs for ceftazidime. In
one of these isolates, sequence analysis of the K1 enzyme
showed a mutation resulting in a proline-to-serine substitu-
tion at position 167 which has been described twice earlier
and results in resistance to ceftazidime.13,18 The phenotypic
detection of ESBLs in K. oxytoca is known to be difficult be-
cause of the presence of the chromosomal K1 enzyme that
causes false-positive screen and confirmatory test results,
and all tests were unreliable in our study as in other stud-
ies.25 K. oxytoca with no ESBL gene detected, susceptibility to
ceftazidime, a negative ESBL phenotype using ceftazidime,
and a positive ESBL phenotype using cefotaxime is the phe-
notype consistent with hyperproduction of the K1 enzyme.25
This was the case in 12 of the 21 K. oxytoca isolates using
Etest. Interestingly, the DDS test using ceftazidime and
cefotaxime did not result in false positives as described re-
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cently, but instead could not detect the four TEM-derived
ESBLs.25 The phenotypic confirmation of ESBLs in K. oxytoca
that showed increased MIC for cefotaxime but not ceftazi-
dime remains problematic. As Carter et al. showed good
performance of the DDS test using cefpodoxime, we repeated
this test with all K. oxytoca isolates; however, the results re-
mained unchanged (data not shown), and the previously
reported good performance may be explained by the selec-
tion of the isolates tested.5
The prevalence of ESBL in The Netherlands is increasing
but still relatively low compared with most other European
countries, and this may change rapidly. The variety of ESBL
genes detected in the isolates illustrates the extent of ESBL-
mediated resistance in our setting. The ESBL genes detected
were comparable to other international studies. Current mo-
lecular and phenotypic detection methods have important
shortcomings complicating epidemiological studies and the
routine detection of ESBLs by the clinical laboratory. While
overdetection results in inappropriate use of broad-spectrum
antibiotics further complicating the resistance problem, under-
detection may result in treatment failure and uncontrolled
spread.
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